Campbell & Co Investment Adviser’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-46,674
Closed -$5.5M 1308
2026
Q1
$5.5M Buy
+46,674
New +$6.52M 0.31% 57
2025
Q4
Sell
-6,617
Closed -$884K 1363
2025
Q3
$884K Buy
6,617
+407
+7% +$49.4K 0.07% 467
2025
Q2
$772K Buy
+6,210
New +$790K 0.05% 617
2024
Q4
Sell
-2,266
Closed -$337K 1312
2024
Q3
$337K Sell
2,266
-17,621
-89% -$2.53M 0.03% 858
2024
Q2
$2.51M Buy
19,887
+17,114
+617% +$2.68M 0.21% 111
2024
Q1
$510K Sell
2,773
-10,742
-79% -$2.05M 0.04% 679
2023
Q4
$2.43M Buy
+13,515
New +$2.1M 0.22% 86
2022
Q4
Sell
-2,359
Closed -$441K 959
2022
Q3
$441K Buy
2,359
+1,113
+89% +$235K 0.1% 355
2022
Q2
$202K Buy
+1,246
New +$197K 0.05% 605
2022
Q1
Sell
-3,350
Closed -$887K 866
2021
Q4
$887K Buy
+3,350
New +$903K 0.3% 75
2019
Q4
Sell
-4,213
Closed -$323K 820
2019
Q3
$323K Buy
+4,213
New +$368K 0.12% 355
2015
Q1
Sell
-13,649
Closed -$270K 270
2014
Q4
$270K Buy
+13,649
New +$305K 0.17% 171

Other funds holding RGEN

Campbell & Co Investment Adviser's RGEN Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Repligen (RGEN) in Q2 2026, closing a stake of 46,674 shares — an estimated $5.5M sold.

Campbell & Co Investment Adviser first reported a position in RGEN in Q4 2014 and held it in 12 quarters. The position peaked at $5.5M in Q1 2026. 213 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Repligen position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 46,674 Repligen shares in Q2 2026, an estimated $5.5M.
  • Campbell & Co Investment Adviser first reported a position in Repligen in Q4 2014 and held it in 12 quarters.
  • Campbell & Co Investment Adviser's Repligen position peaked at $5.5M in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.